461 related articles for article (PubMed ID: 21832239)
1. Curaxins: anticancer compounds that simultaneously suppress NF-κB and activate p53 by targeting FACT.
Gasparian AV; Burkhart CA; Purmal AA; Brodsky L; Pal M; Saranadasa M; Bosykh DA; Commane M; Guryanova OA; Pal S; Safina A; Sviridov S; Koman IE; Veith J; Komar AA; Gudkov AV; Gurova KV
Sci Transl Med; 2011 Aug; 3(95):95ra74. PubMed ID: 21832239
[TBL] [Abstract][Full Text] [Related]
2. Curaxins: a new family of non-genotoxic multitargeted anticancer agents.
Di Bussolo V; Minutolo F
ChemMedChem; 2011 Dec; 6(12):2133-6. PubMed ID: 22038935
[No Abstract] [Full Text] [Related]
3. Cancer drug discovery faces the FACT.
Draetta GF; Depinho RA
Sci Transl Med; 2011 Aug; 3(95):95ps34. PubMed ID: 21832237
[TBL] [Abstract][Full Text] [Related]
4. Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs.
Nesher E; Safina A; Aljahdali I; Portwood S; Wang ES; Koman I; Wang J; Gurova KV
Cancer Res; 2018 Mar; 78(6):1431-1443. PubMed ID: 29339544
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
7. Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.
Song H; Zeng J; Roychoudhury S; Biswas P; Mohapatra B; Ray S; Dowlatshahi K; Wang J; Band V; Talmon G; Bhakat KK
Mol Cancer Ther; 2020 Jan; 19(1):258-269. PubMed ID: 31575655
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling.
Hwang SG; Park J; Park JY; Park CH; Lee KH; Cho JW; Hwang JI; Seong JY
PLoS One; 2012; 7(9):e44259. PubMed ID: 23028510
[TBL] [Abstract][Full Text] [Related]
9. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of FACT removal from transcribed genes by anticancer drugs curaxins.
Chang HW; Valieva ME; Safina A; Chereji RV; Wang J; Kulaeva OI; Morozov AV; Kirpichnikov MP; Feofanov AV; Gurova KV; Studitsky VM
Sci Adv; 2018 Nov; 4(11):eaav2131. PubMed ID: 30417101
[TBL] [Abstract][Full Text] [Related]
11. Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-κB pathway.
Zhuang C; Miao Z; Wu Y; Guo Z; Li J; Yao J; Xing C; Sheng C; Zhang W
J Med Chem; 2014 Feb; 57(3):567-77. PubMed ID: 24428757
[TBL] [Abstract][Full Text] [Related]
12. Nuclear factor-(kappa)B modulates the p53 response in neurons exposed to DNA damage.
Aleyasin H; Cregan SP; Iyirhiaro G; O'Hare MJ; Callaghan SM; Slack RS; Park DS
J Neurosci; 2004 Mar; 24(12):2963-73. PubMed ID: 15044535
[TBL] [Abstract][Full Text] [Related]
13. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.
Gomes NP; Bjerke G; Llorente B; Szostek SA; Emerson BM; Espinosa JM
Genes Dev; 2006 Mar; 20(5):601-12. PubMed ID: 16510875
[TBL] [Abstract][Full Text] [Related]
14. The Current Status of SSRP1 in Cancer: Tribulation and Road Ahead.
Jia S; Guo B; Wang L; Peng L; Zhang L
J Healthc Eng; 2022; 2022():3528786. PubMed ID: 35463672
[TBL] [Abstract][Full Text] [Related]
15. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
16. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
Chen F; Qin X; Xu G; Gou S; Jin X
Biochem Pharmacol; 2017 Jul; 135():50-68. PubMed ID: 28288821
[TBL] [Abstract][Full Text] [Related]
17. Novel derivative of benzofuran induces cell death mostly by G2/M cell cycle arrest through p53-dependent pathway but partially by inhibition of NF-kappaB.
Manna SK; Bose JS; Gangan V; Raviprakash N; Navaneetha T; Raghavendra PB; Babajan B; Kumar CS; Jain SK
J Biol Chem; 2010 Jul; 285(29):22318-27. PubMed ID: 20472557
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
[TBL] [Abstract][Full Text] [Related]
19. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1.
Keller DM; Zeng X; Wang Y; Zhang QH; Kapoor M; Shu H; Goodman R; Lozano G; Zhao Y; Lu H
Mol Cell; 2001 Feb; 7(2):283-92. PubMed ID: 11239457
[TBL] [Abstract][Full Text] [Related]
20. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.
Dey A; Wong ET; Cheok CF; Tergaonkar V; Lane DP
Cell Death Differ; 2008 Feb; 15(2):263-73. PubMed ID: 17975552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
